Dazler

Uk Based Researcher and Investor of
Medical licenced Cannabis with an NHS pathway focus to Improve People's Well being and Take the pain away!

[Ananda Pharma @AnandaPharma]

New RCT evidence in anorexia nervosa adds to a growing body of clinical signals for high-dose purified CBD. The dosing used sits in the same broad range as Ananda's own Phase I and planned Phase II programmes. From epilepsy to rare heart failure to anorexia, a consistent pattern is emerging: pharmaceutical-grade CBD at the right dose, in properly designed trials, produces measurable effects. That is precisely the thesis underpinning MRX1 and our ENDOCAN-1 and ACTION studies.

https://t.co/jEFgk27Md6

#CBD #MRX #endometriosis #CIPN #clinicaltrials

[Dazler @60Toad60]

#endometriosis @Endofound

[Dazler @60Toad60]

Listening to "Forum Radio: Melissa Sturgess" at https://t.co/SGT991Tjpq
Yes I'm invested and this will fulfill such an unmet need get listening and see the drive coming from the Team at Ananda pharma

[Ananda Pharma @AnandaPharma]

Ananda has just received MHRA and NHS Ethics approval for ENDOCAN-1, our Phase 2 clinical trial testing MRX1 CBD oral solution for endometriosis-associated pain. 190 million women live with this condition. Current treatments fail too many of them. We're changing that. Up to 100 women. 12 weeks. World-class researchers at the University of Edinburgh. Recruitment opens soon.

Read the full announcement here: https://t.co/47t96s6h5d

#Endometriosis #WomensHealth #ClinicalTrial #CBD #MRX1 #ENDOCAN #AnandaPharma #Biotech

[Ananda Pharma @AnandaPharma]

Jack Morgan represented Ananda at JP Morgan Healthcare Week last month, and the week reinforced something critical, that real momentum is building in the sector. The full article is available here: https://t.co/jY7AEQ7yG8

Large pharma companies facing the patent cliff are actively seeking partnerships with focused biotech in areas of unmet need.

What Jack heard repeatedly from investors and companies is that they want shorter timelines to market, robust clinical trial data, and measurable outcomes.

This isn't news to us. This is exactly where Ananda has positioned itself.

Jack met with investors, pharmaceutical partners, and service providers for our US expansion. He attended sessions on women's health and AI in healthcare. Most importantly, he left energized by the opportunities ahead.

#Biotech #WomensHealth #HealthcareInnovation

[Dazler @60Toad60]

@AnandaPlc Ananda perfectly positioned

[Dazler @60Toad60]

@AnandaPlc Big year for Ananda bring it on!

[Ananda Pharma @AnandaPharma]

In case you missed it...on 21 January, Ananda's CEO, Melissa Sturgess, and CCO, Jack Morgan, gave a presentation on Ananda and what the year ahead has in store for the Company. For those who were unable to join live, we’ve made the webinar recording and slides available via the link below.

https://t.co/XrcgV7GNcX

If you have any questions, please email [email protected] or leave a comment below.

#ANA #presentation #update

[Ananda Pharma @AnandaPharma]

We’ve shared our January 2026 Shareholder Update, outlining our transition to a private company, progress across our clinical trials, and priorities for the year ahead.
Join our live shareholder webinar on Wednesday 21 January at 10am to hear directly from the team and ask questions.
Register via: https://t.co/NzZVyorDia

#ANA #MRX1 #clinicaltrials

[Dazler @60Toad60]

@ABridgen Public enemy no 1 now needs to leave no 10

[Ananda Pharma @AnandaPharma]

Ananda Pharma welcomes the move as we advance MRX1 toward US Phase 2 trials.

#Biotech #CBD #ClinicalResearch

[Ananda Pharma @AnandaPharma]

President Trump signs Executive Order rescheduling cannabis from Schedule 1 to Schedule 3.

A federal acknowledgement of medical use that supports faster research, FDA pathways, and access to capital.

[Dazler @60Toad60]

Green one

[Dazler @60Toad60]

@oelma__ 18

[Dazler @60Toad60]

@AnandaPlc Fantastic news for the Team and shareholders

[Ananda Pharma @AnandaPharma]

Ananda Pharma has received combined ethics + MHRA approval for our Phase 2 trial of MRX1 in Chemotherapy-Induced Peripheral Neuropathy (CIPN). 20251110 CIPN ethics approval.

CIPN has no approved treatments and affects 140k+ new UK patients yearly. Recruitment next. Updates to follow.

Click here for the full announcement and to ask any questions: https://t.co/C0Ue33CXWL

#ClinicalTrials #CIPN #Oncology #MRX1 #nihrprcs

@SturgessMelissa

[Dazler @60Toad60]

@AntiWokeMemes Been band

[Dazler @60Toad60]

@EshaAA33 15

[Dazler @60Toad60]

@Matt_Pinner 2

[Dazler @60Toad60]

@edmcdermott12 @DanielPriestley I'm ready to leave too